Literature DB >> 27220814

Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease.

E M Giles1,2, T J Sanders3, N E McCarthy1, J Lung1, M Pathak1, T T MacDonald1, J O Lindsay1, A J Stagg1.   

Abstract

Type 1 interferon (IFN-1) promotes regulatory T-cell function to suppress inflammation in the mouse intestine, but little is known about IFN-1 in the human gut. We therefore assessed the influence of IFN-1 on CD4+ T-cells isolated from human colon tissue obtained from healthy controls or patients with inflammatory bowel disease (IBD). Immunofluorescent imaging revealed constitutive expression of IFNβ in human intestinal tissue, and colonic T-cells were responsive to exogenous IFN-1 as assessed by phosphorylation of signal transduction and activator of transcription 1 (pSTAT1) and induction of interferon stimulated genes (ISGs). Unlike their blood counterparts, intestinal T-cells from non-inflamed regions of IBD colon displayed enhanced responsiveness to IFN-1, increased frequency of pSTAT1+ cells, and greater induction of ISGs upon IFN-1 exposure in vitro. In healthy tissue, antibody neutralization of IFNβ selectively reduced T-cell production of the pro-regulatory cytokine interleukin-10 (IL-10) and increased IFNγ synthesis. In contrast, neutralization of IFNβ in IBD tissue cultures increased the frequency of T-cells producing inflammatory cytokines but did not alter IL-10 expression. These data support a role for endogenous IFN-1 as a context-dependent modulator of T-cell function that promotes regulatory activity in healthy human intestine, but indicate that the IFN-1/STAT1 pathway is dysregulated in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27220814     DOI: 10.1038/mi.2016.44

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  38 in total

Review 1.  Constitutive type I interferon modulates homeostatic balance through tonic signaling.

Authors:  Daniel J Gough; Nicole L Messina; Christopher J P Clarke; Ricky W Johnstone; David E Levy
Journal:  Immunity       Date:  2012-02-24       Impact factor: 31.745

2.  Characteristics of intestinal dendritic cells in inflammatory bowel diseases.

Authors:  Ailsa L Hart; Hafid Omar Al-Hassi; Rachael J Rigby; Sally J Bell; Anton V Emmanuel; Stella C Knight; Michael A Kamm; Andrew J Stagg
Journal:  Gastroenterology       Date:  2005-07       Impact factor: 22.682

3.  T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells.

Authors:  Claudia Hofmann; Nadja Dunger; Nicole Grunwald; Günter J Hämmerling; Petra Hoffmann; Jürgen Schölmerich; Werner Falk; Florian Obermeier
Journal:  Gut       Date:  2010-08-23       Impact factor: 23.059

4.  Migration and maturation of human colonic dendritic cells.

Authors:  S J Bell; R Rigby; N English; S D Mann; S C Knight; M A Kamm; A J Stagg
Journal:  J Immunol       Date:  2001-04-15       Impact factor: 5.422

Review 5.  Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases.

Authors:  Warren Strober; Ivan J Fuss
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

6.  Disease-specific alterations in the enteric virome in inflammatory bowel disease.

Authors:  Jason M Norman; Scott A Handley; Megan T Baldridge; Lindsay Droit; Catherine Y Liu; Brian C Keller; Amal Kambal; Cynthia L Monaco; Guoyan Zhao; Phillip Fleshner; Thaddeus S Stappenbeck; Dermot P B McGovern; Ali Keshavarzian; Ece A Mutlu; Jenny Sauk; Dirk Gevers; Ramnik J Xavier; David Wang; Miles Parkes; Herbert W Virgin
Journal:  Cell       Date:  2015-01-22       Impact factor: 41.582

7.  Localized delivery of interferon-β by Lactobacillus exacerbates experimental colitis.

Authors:  Adelle P McFarland; Ram Savan; Sagie Wagage; Augustina Addison; Karthika Ramakrishnan; Megan Karwan; Tri Duong; Howard A Young
Journal:  PLoS One       Date:  2011-02-18       Impact factor: 3.240

8.  Blockade of chronic type I interferon signaling to control persistent LCMV infection.

Authors:  Elizabeth B Wilson; Douglas H Yamada; Heidi Elsaesser; Jonathan Herskovitz; Jane Deng; Genhong Cheng; Bruce J Aronow; Christopher L Karp; David G Brooks
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

9.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

10.  Immunology. An interferon paradox.

Authors:  Pamela M Odorizzi; E John Wherry
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

View more
  17 in total

1.  Evaluation of Intestinal Epithelial Barrier Function in Inflammatory Bowel Diseases Using Murine Intestinal Organoids.

Authors:  Harikrishna Reddy Rallabandi; Hyeon Yang; Keon Bong Oh; Hwi Cheul Lee; Sung June Byun; Bo Ram Lee
Journal:  Tissue Eng Regen Med       Date:  2020-06-27       Impact factor: 4.169

2.  Disease Risk-Associated Genetic Variants in STAT1 and STAT4 Function in a Complementary Manner to Increase Pattern-Recognition Receptor-Induced Outcomes in Human Macrophages.

Authors:  Matija Hedl; Rui Sun; Clara Abraham
Journal:  J Immunol       Date:  2020-07-13       Impact factor: 5.422

3.  STAT1-mediated induction of Ly6c-expressing macrophages are involved in the pathogenesis of an acute colitis model.

Authors:  Shuhei Kii; Hidemitsu Kitamura; Shinichi Hashimoto; Kazuho Ikeo; Nobuki Ichikawa; Tadashi Yoshida; Shigenori Homma; Mishie Tanino; Akinobu Taketomi
Journal:  Inflamm Res       Date:  2022-08-01       Impact factor: 6.986

4.  p300 Serine 89: A Critical Signaling Integrator and Its Effects on Intestinal Homeostasis and Repair.

Authors:  Keane K Y Lai; Xiaohui Hu; Keisuke Chosa; Cu Nguyen; David P Lin; Keith K Lai; Nobuo Kato; Yusuke Higuchi; Sarah K Highlander; Elizabeth Melendez; Yoshihiro Eriguchi; Patrick T Fueger; Andre J Ouellette; Nyam-Osor Chimge; Masaya Ono; Michael Kahn
Journal:  Cancers (Basel)       Date:  2021-03-14       Impact factor: 6.639

5.  A Notch/STAT3-driven Blimp-1/c-Maf-dependent molecular switch induces IL-10 expression in human CD4+ T cells and is defective in Crohn´s disease patients.

Authors:  Christian Neumann; Alexander Scheffold; Jonas Ahlers; Andrej Mantei; Laura Lozza; Manuela Stäber; Frederik Heinrich; Petra Bacher; Thordis Hohnstein; Lutz Menzel; Simge G Yüz; Daniel Alvarez-Simon; Anne Rieke Bickenbach; Carl Weidinger; Nadine Mockel-Tenbrinck; Anja A Kühl; Britta Siegmund; Jochen Maul
Journal:  Mucosal Immunol       Date:  2022-02-15       Impact factor: 8.701

Review 6.  Intestinal Autophagy and Its Pharmacological Control in Inflammatory Bowel Disease.

Authors:  Ping Ke; Bo-Zong Shao; Zhe-Qi Xu; Xiong-Wen Chen; Chong Liu
Journal:  Front Immunol       Date:  2017-01-09       Impact factor: 7.561

7.  Interferon-Alpha Promotes Th1 Response and Epithelial Apoptosis via Inflammasome Activation in Human Intestinal Mucosa.

Authors:  Anne Jarry; Florent Malard; Chantal Bou-Hanna; Guillaume Meurette; Mohamad Mohty; Jean-François Mosnier; Christian L Laboisse; Céline Bossard
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-09-20

Review 8.  Type I and III Interferon in the Gut: Tight Balance between Host Protection and Immunopathology.

Authors:  Johanna Pott; Silvia Stockinger
Journal:  Front Immunol       Date:  2017-03-14       Impact factor: 7.561

Review 9.  Impact of Paneth Cell Autophagy on Inflammatory Bowel Disease.

Authors:  Shu-Ling Wang; Bo-Zong Shao; Sheng-Bing Zhao; Jun Fang; Lun Gu; Chao-Yu Miao; Zhao-Shen Li; Yu Bai
Journal:  Front Immunol       Date:  2018-04-05       Impact factor: 7.561

Review 10.  Transcriptional Regulation of Macrophages Polarization by MicroRNAs.

Authors:  Heng Li; Ting Jiang; Meng-Qi Li; Xi-Long Zheng; Guo-Jun Zhao
Journal:  Front Immunol       Date:  2018-05-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.